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The deterioration of the inner blood-retinal barrier
and consequent macular edema is a cardinal mani-
festation of diabetic retinopathy (DR) and the clinical
feature most closely associated with loss of sight.
We provide evidence from both human and animal
studies for the critical role of the classical neuronal
guidance cue, semaphorin 3A, in instigating patho-
logical vascular permeability in diabetic retinas via
its cognate receptor neuropilin-1. We reveal that
semaphorin 3A is induced in early hyperglycemic
phases of diabetes within the neuronal retina and
precipitates initial breakdown of endothelial barrier
function. We demonstrate, by a series of orthogonal
approaches, that neutralization of semaphorin 3A
efficiently prevents diabetes-induced retinal vas-
cular leakage in a stage of the disease when vascular
endothelial growth factor neutralization is inefficient.
These observations were corroborated in TgCre-Esr1/
Nrp1flox/flox conditional knockout mice. Our findings
identify a therapeutic target for macular edema and
provide further evidence for neurovascular crosstalk
in the pathogenesis of DR.
INTRODUCTION
Diabetic retinopathy (DR) is the most prominent complication
of diabetes and the leading cause of blindness in working-age
individuals (Kempen et al., 2004). It is characterized by an initial
microvascular degeneration followed by a compensatory but
pathological hypervascularizationmounted by the hypoxic retina
in an attempt to reinstate metabolic equilibrium (Cheung and
Wong, 2008; Sapieha, 2012). Although often initially asymptom-
atic, loss of sight is provoked primarily by diabetic macular
edema (DME), vitreous hemorrhages, and in advanced cases,
preretinal neovascularization and tractional retinal detachment
(Antonetti et al., 2012; Wang et al., 2012). Of these, DME is the
most common cause of central vision loss in diabetics, affectingCellover 25% of patients suffering from diabetes (Moss et al., 1998).
It is triggered secondary to the deterioration of the blood-retinal
barrier (BRB) and the consequent increase in extravasation of
fluids and plasma components into the vitreous cavity. Ulti-
mately, the decrease in retinal vascular barrier function leads
to vasogenic edema and pathological retinal thickening.
Although significant effort has been invested in elucidating the
mechanisms that govern destructive preretinal neovasculariza-
tion in DR (Silva et al., 2010; Stahl et al., 2010; Wang et al.,
2012), considerably less is known about the cellular processes
that lead to increased retinal vascular permeability. Moreover,
current standards of care present non-negligible side effects.
These include increased cataract formation and a harmful rise
in intraocular pressure with intravitreal use of corticosteroid
(Silva et al., 2010). Similarly, anti-VEGF (vascular endothelial
growth factor) therapies, which in general exhibit respectable
safety profiles, may be associated with increased thromboem-
bolic events (Stewart, 2012), possible neuronal toxicity (Foxton
et al., 2013; Robinson et al., 2001; Saint-Geniez et al., 2008),
and geographic atrophy (Martin et al., 2011; 2012) when used
as frequent long-term regimens. Moreover, the first and most
widely used form of treatment is panretinal photocoagulation,
for either proliferative diabetic retinopathy (PDR) or grid/focal
laser for DME. Laser-based photocoagulation approaches
destroy hypoxic retinal tissue secreting proangiogenic factors
and inadvertently lead to reduced visual field or central or para-
central scotomas. These therapeutic limitations highlight the
need for novel pharmacological interventions.
Current investigations into the molecular mechanisms that
cause DME have largely focused on VEGF. This may be attrib-
uted in part to the fact that the prominent clinical features of
DR have led to the general inference that it is entirely of a micro-
vascular nature. Yet, evidence points to early changes in the
neural retina (Kern and Engerman, 1996; Barber et al., 1998;
2005; Gastinger et al., 2008). While there is irrefutable evidence
for a neurovascular link in the progression of DR (Antonetti et al.,
2012), neurovascular crosstalk has received limited attention in
the context of DR pathogenesis. Consistent with a breakdown
in neurovascular crosstalk in ischemic retinopathies, we
have recently shown that semaphorin 3A (SEMA3A), a classic
neuronal guidance cue that also affects endothelial cell behavior,
is produced by stressed retinal ganglion cells (RGCs) andMetabolism 18, 505–518, October 1, 2013 ª2013 Elsevier Inc. 505
Table 1. Characteristics of Patients Having Undergone Vitreous
Biopsy
Sample
Age
(Years) Db Type
Duration
(Years) Retinopathy Analysis
C1 65 NA NA ERM WB/ELISA
C2 74 NA NA MH WB/ELISA
C3 63 NA NA MH WB
C4 71 NA NA MER WB
C5 78 NA NA other WB
C6 59 NA NA MH ELISA
C7 52 NA NA MH ELISA
C8 59 NA NA MH ELISA
C9 69 NA NA ERM ELISA
C10 54 NA NA ERM ELISA
C11 68 NA NA ERM ELISA
DME1 74 2 2 DME WB/ELISA
DME2 75 2 10 DME WB/ELISA
DME3 69 2 20 DME WB/ELISA
DME4 49 2 3 DME WB/ELISA
DME5 74 2 15 DME WB/ELISA
DME6 76 2 30 DME WB/ELISA
DME7 81 2 – DME WB/ELISA
DME8 74 2 15 DME WB
DME9 62 2 22 DME ELISA
DME10 63 2 23 DME ELISA
Demographics of patients selected for vitreous biopsy. Vitreous samples
were obtained from 11 controls (nonvascular pathology) and 10 DME pa-
tients and analyzed by western blot and ELISA. C, control (nonvascular
pathology); Db, diabetes; DME, diabetic macular edema; ERM, epiretinal
membrane; MH, macular hole; NA, not applicable; WB, western blot.
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cular regions of the eye (Joyal et al., 2011).
In neurons, binding of SEMA3A to its cognate receptor neuro-
pilin-1 (NRP1) provokes cytoskeletal collapse via plexins (Taka-
hashi et al., 1999); the transduction mechanism in endothelial
cells remains ill defined (Gelfand et al., 2009). Neuropilin-1 has
the particular ability to bind two structurally dissimilar ligands
via distinct sites on its extracellular domain (Gluzman-Poltorak
et al., 2001; Lee et al., 2002; Mamluk et al., 2002). It binds
SEMA3A (Klagsbrun and Eichmann, 2005; Miao et al., 1999),
provoking cytoskeletal collapse and VEGF165 (Gluzman-Poltorak
et al., 2001; Klagsbrun and Eichmann, 2005; Klagsbrun et al.,
2002; Mamluk et al., 2002), enhancing binding to VEGFR2, and
thus increasing its angiogenic potential (Soker et al., 2002).
Crystallographic evidence revealed that VEGF165 and Sema3A
do not directly compete for Nrp1, but rather can simultaneously
bind to Nrp1 at distinct, nonoverlapping sites (Appleton et al.,
2007). Moreover, genetic studies show that NRP1 distinctly
regulates the effects of VEGF and SEMA3A on neuronal and
vascular development (Vieira et al., 2007). Notably, it was pro-
posed that, similar to VEGF, Sema3A may itself promote
vascular permeability (Acevedo et al., 2008); this is a counterin-
tuitive observation, given the divergent biological roles of VEGF
and Sema3A. However, the role of Sema3A in mediating the
breakdown of barrier function, such as that observed in diabetic
retinopathy, has not been explored to date.
Here we provide evidence for the role of a neuron-derived
guidance cue (Sema3A) in disrupting retinal barrier function in
diabetic retinopathy. We demonstrate in both human patients
and animal models that ocular Sema3A is robustly induced in
the early stages of diabetes and mediates, via NRP1, the break-
down of the inner BRB. Neutralizing Sema3A may represent an
attractive alternative therapeutic strategy to counter pathologic
vascular permeability in DR.
RESULTS
Sema3A Is Elevated in the Vitreous of Human Patients
Suffering from Diabetic Retinopathy
In order to evaluate the potential role of Sema3A in mediating the
edematous phenotype observed in DR, we first sought to deter-
mine the presence of this guidance cue in the vitreous of patients
suffering from DME. Vitreous was recovered during standard
vitroretinal surgery from 21 patients. Ten samples were obtained
from patients suffering from DME and 11 from control patients
(nonvascular pathology) undergoing surgery for macular hole
(MH) or epiretinal membrane (ERM) (Table 1). Spectral-domain
optical coherence tomography (SD-OCT) was performed, and
three-dimensional (3D) retinal maps were generated to evaluate
the extent of retinal damage and edema. In contrast to controls,
sampled DME patients showed significant retinal swelling, spe-
cifically in the macular and perimacular zones (Figures 1A–1D).
Consistentwithaprospective role inDME,ELISA-baseddetec-
tion of Sema3A revealed a significant increase in the vitreous of
patients suffering from DME when compared to nonvascular
ocular pathologies (control median 3.79 ng/ml [interquartile
range {IQR}: 25%, 75%: 2.08 ng/ml, 5.58 ng/ml]; DME median
16.27 ng/ml [IQR: 25%, 75%: 5.770 ng/ml, 35.36 ng/ml];
p = 0.0464) (Figure 1E). Western blot analysis of vitreous from506 Cell Metabolism 18, 505–518, October 1, 2013 ª2013 Elsevier Inpatients corroborated data obtained by ELISA and revealed
that Sema3A (125 kDa and 95kDa) (Klebanov et al., 2009;
Koppel and Raper, 1998) was robustly induced in most patients
affected by DME (Figure 1F). Specificity of the a-Sema3A anti-
body employed was verified by shRNA-mediated knockdown
of Sema3A in human cells expressing high levels of endogenous
Sema3A (HeLa) and by immunoblotting serially diluted recom-
binant Sema3A protein (Figure S1 available online). Detailed
patient characteristics are presented in Table 1. These data on
human subjects provide the rationale to explore the role of
Sema3A in the context of diabetes-induced BRB breakdown.
Neuronal SEMA3A Is Upregulated in the Early Phases
of Streptozotocin-Induced Diabetes
Given the elevated levels of Sema3A in the vitreous of DME
patients, we sought to elucidate the dynamics and pattern of
Sema3A expression in amousemodel of type 1 diabetesmellitus
(T1DM). Streptozotocin (STZ) was administered over 5 consecu-
tive days to 6-week-old C57BL/6J mice, and glycemia was
monitored according to the scheme depicted in Figure 2A (modi-
fied from Xu et al., 2001). Mice were considered diabetic if their
nonfasted glycemia was higher than 17 mM (300 mg/dl).
As early as 4 weeks after induction of diabetes, retinal levels
of Sema3A were over 2-fold higher in STZ-treated mice
when compared to vehicle-injected controls, while VEGF levelsc.
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Figure 1. Sema3A Is Elevated in the Vitre-
ous of Human Diabetic Patients Suffering
from Diabetic Retinopathy
(A and B) Spectral domain optical coherence
tomography (SD-OCT) (A) and 3D retinal maps
from healthy eyes (B).
(C and D) In patients suffering from DME, signifi-
cant retinal swelling (C) mostly in the macular and
perimacular zones was noted (D).
(E) ELISA of vitreous humor for Sema3A from
control patients with nonvascular pathology and
patients suffering from DME. Horizontal lines
represent medians for each group.
(F) Western blot analysis of equal volumes of
vitreous humor revealed a pronounced induction
of Sema3A (125 kDa and 95 kDa) in a number
of patients suffering from DME. See Figure S1 for
antibody specificity.
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Sema3A, 2.234 ± 0.214; p = 0.0045; Vegf, 1.123 ± 0.192; p =
0.559, n = 5) (Figure 2B). Significantly higher retinal levels of
Sema3A persisted at 8 weeks (Sema3A, 2.80 ± 0.340; p =
0.0011; Vegf, 1.236 ± 0.193; p = 0.266, n = 8), 12 weeks
(Sema3A, 4.07 ± 0.798; p = 0.00846; Vegf, 0.923 ± 0.145; p =
0.612, n = 4), and 14 weeks (Sema3A, 2.44 ± 0.593; p =
0.0334; Vegf, 3.26 ± 0.65; p = 0.0253, n = 3). Importantly,
throughout the early time points of diabetes, VEGF levels in
STZ-treated mice remained at similar levels to that observed in
vehicle-treated littermates, as has been previously described
(Mima et al., 2012), and only started to increase at 14 weeks.
The rise in retinal SEMA3A in diabetic mice was confirmed by
western blotting at 8 and 14 weeks (Figure 2C). As expected,
at all analyzed time points, STZ-treated mice showed patholog-
ically elevated blood glucose levels of30 mM for both 4 weeks
(citrate, 10.36 ± 0.2935; STZ, 28.81 ± 2.204; p < 0.0001, n = 7)Cell Metabolism 18, 505–518and 8 weeks of diabetes (citrate,
10.72 ± 0.3030; STZ, 27.70 ± 1.780; p <
0.0001, n = 11) (Figure 2D). To corrobo-
rate that the observed rise in retinal
SEMA3A was provoked by the diabetic
state of mice and not STZ toxicity, we
investigated retinal Sema3A expression
in leptin-receptor-deficient (db/db) mice,
which are a model of type 2 diabetes
mellitus (Sapieha et al., 2012). At
24 weeks of life, db/db mice showed a
2.5-fold increase in levels of retinal
Sema3A mRNA when compared to het-
erozygous db/+ controls (2.5 ± 0.05; p =
0.0013, n = 3). These data suggest that
Sema3A was induced as a consequence
of diabetes and not off-target effects of
STZ (Figure S2).
Importantly, the rise inSema3A expres-
sion was an early event in pathogenesis,
as it preceded pericyte loss, becauseboth STZ- and vehicle-treated mice showed no significant differ-
ence in transcript levels for pericyte markers platelet-derived
growth factor receptor-b (Pdgfr-b; 1.477 ± 0.364; p = 0.219, n =
11), NG2 proteoglycan (Ng2; 2.065 ± 0.886; p = 0.316, n = 4),
or alpha smooth muscle actin (a-Sma; 1.342 ± 0.441; p =
0.494, n = 4) (Figure 2E). Similarly, immunofluorescence on retinal
flatmounts from control and STZ animals confirmed similar
vascular coverage by NG2 and SMA-expressing pericytes (Fig-
ures 2F–2I).
We next investigated the cellular localization of SEMA3A in the
diabetic mouse retina. Immunofluorescence on retinal cryosec-
tions revealed that SEMA3A was strongly expressed by retinal
neurons of the ganglion cell layer (GCL) (Figures 2J and 2K).
Colocalization with the RGC marker bIII-tubulin confirmed that
SEMA3A localized to retinal ganglion cells (RGCs) within the
diabetic retina (Figure 2K, inset). Consistent with this retinal
immunolocalization, laser-capture microdissection of the retinal, October 1, 2013 ª2013 Elsevier Inc. 507
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Figure 2. Neuronal Sema3A Is Upregulated in the Early Phases of Streptozotocin-Induced Diabetes
(A) Streptozotocin (STZ) was administered to6-week-old C57BL/6Jmice, and glycemia wasmonitored according to scheme; amouse with nonfasted glycemia
higher than 17 mM (300 mg/dl) was considered diabetic.
(legend continued on next page)
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quantitative RT-PCR revealed an 5-fold increase of Sema3A
transcript in RGCs from STZ retinas when compared to age-
matched nondiabetic controls (4.848 ± 0.9178; p = 0.014,
n = 3) (Figures 2L and 2M). These data provide evidence for
the local production of SEMA3A by diabetic neurons in close
proximity to the retinal vascular plexus and agree with a role
for SEMA3A in mediating the vascular phenotype associated
with DME and PDR.
Retinal Barrier Function Is Compromised by SEMA3A
Given the increase in levels of retinal Sema3A observed in the vit-
reous samples of patients with DME and SEMA3A in mouse ret-
inas in the early stages of diabetes (Figure 2), we proceeded to
investigate the propensity of Sema3A to disrupt vascular barrier
function. We tested concentrations of Sema3A detected in the
vitreous of patients with DME (Figure 1). Because we are assess-
ing acute retinal vascular permeability at 24 hr postinjection and
not a protracted effect as would be expected in actual human
DME, the tested concentrations of Sema3A were ascending
from the pathophysiological levels detected in Figure 1. Retinal
vascular permeability was determined by Evans blue (EB)
permeation after a single intravitreal injection of Sema3A into
adult mouse eyes. Vascular leakage augmented step-wise with
increasing concentrations of Sema3A. The increase in vascular
leakage reached significance at 25 ng/ml of Sema3A and rose
thereafter (mean fold increase over vehicle control ± SEM:
25 ng/ml, 1.302 ± 0.005; p = 0.0003; 50 ng/ml, 1.648 ± 0.059;
p = 0.0082; 100 ng/ml, 2.21 ± 0.140; p = 0.0131; 200 ng/ml,
2.57 ± 0.0967; p = 0.0038) (Figure 3A). Concordantly, wet
weights of retinas were measured directly upon removing the
retina from the eyecup and increased with higher concentrations
of intravitreal Sema3A (Figure S3). In order to compare the
magnitude of Sema3A-induced retinal vascular permeability
with that of VEGF, we scaled the doses to concentrations of
VEGF previously reported to induce vascular permeability in
murine models (Acevedo et al., 2008) and corrected for molarity.
A single intravitreal injection of VEGF165 (50 ng/ml) induced a
similar magnitude of permeability (1.801 ± 0.0934; p < 0.01) as
Sema3A (100 ng/ml; 2.136 ± 0.392; p < 0.05) or a combination
of both Sema3A and VEGF (2.258 ± 0.411; p < 0.05) (Figure 3B).
Notably, the scaled doses provoked an increase in retinal
vascular permeability similar to those of lower concentration(B) At 4 weeks after induction of diabetes, retinal Sema3A mRNA levels rose mor
(p = 0.0045, n = 5),3-fold at 8 weeks (p = 0.0011, n = 8), 4-fold at 12 weeks (p = 0
levels remained unchanged until 14 weeks, at which point they rose by 3-fold
(C) Western blot analysis of retinas confirmed that protein levels of SEMA3A wer
(D) At all weeks of diabetes, STZ-treated mice showed pathologically elevated b
expression in db/db mice.
(E) The rise in Sema3A expression preceded pericyte loss as evidenced by similar
receptor-b (Pdgfr-b), neuron-glial antigen 2 (Ng2) proteoglycan, and alpha smoot
as mean ± SEM.
(F–I) Equivalent vascular coverage by pericytes 8 weeks after STZ injection as dep
a-Sma (H) and Ng2 (I) in STZ retinas (representative of at least three separate ex
(J and K) Immunofluorescence on retinal cryosections revealed that SEMA3A prote
ganglion cells (RGCs) in the ganglion cell layer (GCL) at 8 weeks after STZ injectio
Representative images of three independent experiments. Scale bar = 20 mm; in
(L andM) Laser-capture micro-dissection of the GCL from normal or diabetic mice
neurons in close proximity to the inner retinal vascular bed (p = 0.014, n = 3). Da
Cell(Figure 3A), suggesting a maximal response of Sema3A-induced
retinal permeability at lower concentrations. Each dose in Fig-
ures 2A and 2B was tested in three distinct experiments with a
total of nine mice each.
The propensity of Sema3A to induce vascular leakage was
corroborated by confocal imaging of retinal sagittal sections
where increased EB permeation (red) throughout the retina sig-
nifies elevated plasma albumin extravasation and translates
into increased retinal edema (Figure 3C). Notably, with an intra-
vitreal injection of Sema3A, compromised barrier function was
also noted in choroidal vessels in addition to retinal vessels.
While the mouse retina does not have a macula proper, the
observed Sema3A-mediated retinal plasma extravasation taken
with the elevated vitreal levels of Sema3A in human patients (Fig-
ure 1) are suggestive of a role inmediating loss of barrier function
in DME.
Further evidence for the ability of Sema3A to compromise
endothelial barrier function was obtained from real-time analysis
of transendothelial electric resistance (Murakami et al., 2008)
(Figures 3D and 3E). Treatment of an intact monolayer of human
umbilical vein endothelial cells (HUVECs) with Sema3A reduced
endothelial monolayer impedance (measured from an interval
between 3.26 hr and 6 hr; 0.048 > p > 0.009; n = 3) and hence
provoked a drop in barrier function in the first 6 hr by amagnitude
similar to, yet lower than, VEGF (measured from an interval
between 1.12 hr and 6 hr; 0.045 > p > 0.001; n = 4) (Figure 3D).
We next proceeded to determine if Sema3A activated clas-
sical signaling pathways that have reported roles in promoting
vascular permeability. In this respect, we investigated (by west-
ern blot analysis) the activation profiles of Src and focal adhesion
kinase (FAK) that are known to transduce extracellular signals
that provoke the loosening of endothelial cell junctions
(Acevedo et al., 2008; Eliceiri et al., 1999; Scheppke et al.,
2008) (Figure 3F). Stimulation of human retinal microvascular
endothelial cells (HRMECs) by either Sema3A (100 ng/ml) or
VEGF (50 ng/ml) lead to robust phosphorylation of Src at
Tyr416 in the activation loop of the kinase domain, which is
reported to enhance enzyme activity (Hunter, 1987) (Fig-
ure 3G). In turn, FAK was phosphorylated on Tyr576 and
Tyr577 (sites for Src kinases) (Figure 3H). Ultimately, the adhe-
rens junction protein vascular endothelial (VE)-cadherin became
phosphorylated on Tyr731, which is a posttranslational modifica-
tion associated with increased vascular permeability (Pottere than 2-fold in STZ-treated mice when compared to vehicle-injected controls
.00846, n = 4), and2.5 fold at 14 weeks (p = 0.0334, n = 3). Conversely, VEGF
(p = 0.0253, n = 3). Data are represented as mean ± SEM.
e elevated in diabetic mice. See Figure S1 for antibody specificity.
lood glucose of 30 mM (p < 0.0001, n = 7). See Figure S2 for retinal Sema3A
levels of transcripts for pericyte-related markers platelet-derived growth factor
h muscle actin (a-Sma) in STZ- and vehicle-treated mice. Data are represented
icted by pericyte-specific markers a-Sma (F) and Ng2 (G) in control retinas and
periments). Scale bar = 100 mm.
in wasminimally expressed in healthy retinas (J) but robustly induced by retinal
n (K), as confirmed by colocalization with the RGC marker bIII-tubulin (insets).
set = 10 mm.
followed by quantitative RT-PCR confirmed an5-fold induction of Sema3A in
ta are represented as mean ± SEM. Scale bar = 20 mm.
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Figure 3. Retinal Barrier Function Is Compromised by SEMA3A
(A) Dose response for Sema3A-induced retinal vascular permeability (VP) as determined by Evans blue (EB) permeation (white bars are vehicle and black bars are
Sema3A treated; n = 3 [9 mice] for each dose). Data are represented as mean ± SEM.
(B) Intravitreal injection of Sema3A resulted in a similar increase in retinal VP (p < 0.01, n = 3 [9mice]) as observedwith intravitreal administration of VEGF (p < 0.05,
n = 3 [9 mice]) and with a combination of both Sema3A and VEGF (p < 0.001, n = 3 [9 mice]). Values expressed relative to vehicle injected retinas ± SEM. See also
Figure S3 for wet weights of Sema3A-treated retinas.
(legend continued on next page)
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Sema3A Induces Vascular Permeability in Diabeteset al., 2005; Schlaepfer et al., 1994) (Figure 3I). Consistent with
the above data on retinal permeability (Figures 3A and 3C), we
did not observe an additive or synergistic effect when stimulation
of HRMECs was performed with a combination of Sema3A and
VEGF, suggesting a potential eventual convergence of signaling
pathways for both factors (Figures 3G–3I).
The ability of an endothelial cell to maintain intact intercellular
junctions dictates the quality of barrier function. We therefore
investigated changes in endothelial cell morphology secondary
to Sema3A exposure. Consistent with a role in inducing vascular
permeability, confocal microscopy of Sema3A-treated HRMECs
revealed pronounced formation of vascular retraction fibers as
determined by VE-cadherin and phalloidin staining (white
arrows; Figure 3J). The retraction was similar to that observed
with VEGF alone or with a combination of VEGF and Sema3A.
Membrane retraction is corroborated by time-lapse imaging,
and the dotted yellow lines represent the cell-cell interface of
two endothelial cells (Figure 3K). While not a direct measure of
cell permeability, these in vitro results highlight the morpholog-
ical changes induced by Sema3A.
Importantly, at the doses employed in our study (100–200 ng/
ml), Sema3A did not induce cell death or apoptosis in HRMECs,
as determined by assessment of activation (cleavage) of cas-
pase-3 (Figure 3L). These data support the role of Sema3A in
mediating the breakdown of endothelial cell barrier function
and further substantiate the involvement of Sema3A in dia-
betes-induced retinal vascular permeability.
Inhibition of Neuron-Derived SEMA3A Efficiently
Reduces Pathological Vascular Permeability in T1DM
To investigate the therapeutic potential of blocking SEMA3A in
diabetic retinopathy, we proceeded to inhibit it using two distinct
approaches: virally delivered interference RNA or a SEMA3A
trap. The magnitude of retinal vascular leakage was assessed
8 weeks after administration of STZ in adult mice. At this time
point, flatmount retinas from STZ mice show elevated expres-
sion of phosphorylated VE-cadherin in lectin-stained retinal
endothelial cells (Figure 4A), and animals have a significant
57% increase in retinal vascular leakage (Figure 4B) (citrate,
1.000 ± 0.1284; STZ, 1.568 ± 0.1323, p = 0.027; n = 4 distinct ex-
periments with a total of 12 mice).
Recent evidence suggests that retinal neurons exert an impor-
tant influence on the blood vessels that perfuse them (Antonetti
et al., 2012; Binet et al., 2013; Fukushima et al., 2011; Joyal et al.,
2011; Kim et al., 2011; Sapieha et al., 2008). In light of the robust
expression of Sema3A in diabetic RGCs (Figure 2), we sought to(C) Confocal images of retinal sections injected with vehicle, VEGF, or Sema3A; re
images of three independent experiments. Scale bar = 30 mm.
(D) Transendothelial resistance measured in real time by ECIS demonstrates that
0.009; n = 3) to a level similar to that observed with VEGF (1.12–6 hr; 0.045 > p >
(E) ECIS measures true barrier function by assessing the resistance of the parac
(F–I) Working hypothesis for Sema3A-mediated vascular permeability (F). Treatme
Src at Tyr416 (G), FAK on Tyr576 and Tyr577 (H), and the adherence junction prot
when simulation was performed with a combination of Sema3A and VEGF. *p <
(J) Confocal microscopy of Sema3A-treated HRMECs revealed formation of va
(white arrows); retraction was similar to that seen with VEGF alone or with a com
(K) Membrane retraction is corroborated by time-lapse imaging, where dotted ye
(L) Sema3A doses employed in our study (100–200 ng/ml) did not induce cell d
Representative images of three independent experiments are shown.
Cellinhibit production of this guidance cue directly in RGCs using a
lentiviral (Lv) vector carrying small hairpin RNAs (shRNAs)
against Sema3A (Joyal et al., 2011). We generated Lv vectors
with a VSVG capsid, which exhibits high tropism for RGCs
when delivered intravitreally (Binet et al., 2013; Joyal et al.,
2011; Sapieha et al., 2008) (Figure 4C). Efficiency of this
approach was confirmed, as a single intravitreal injection of
Lv.shSema3A at 5 weeks of life (1 week prior to STZ administra-
tion) lead to a significant (63%) reduction in retinal Sema3A
expression at the 8-week time point after STZ administration
when all analysis was carried out (mean fold increase over
control ± SEM = 0.3767 ± 0.07911; p = 0.0014, n = 3) (Figure 4D).
Lv.shSema3A-mediated reduction in retinal Sema3A expression
provoked an 50% decrease in vascular leakage when
compared to control Lv.shGFP (0.5105 ± 0.1347; p = 0.022,
n = 3 distinct experiments with a total of 9 mice) (Figure 4E),
thus validating the strategy of targeting Sema3A in neurons of
the GCL to counter pathological vascular leakage in diabetes.
In order to therapeutically neutralize vitreal SEMA3A, we
employed recombinant mouse soluble NRP1 (rmNRP1) as a
bivalent trap for both SEMA3A and VEGF. Neuropilin-1 is a
single-pass receptor with its extracellular domain subdivided
into distinct subdomains of which a1a2 bind SEMA3A and
b1b2 bind VEGF (Geretti et al., 2008) (Figure 4F). Intravitreal
injections of rmNRP1 at 6 and 7 weeks after STZ administration
lead to a 50% reduction in retinal permeability when com-
pared to vehicle-injected controls, as measured at 8 weeks
after STZ (0.5538 ± 0.1459, p = 0.012, n = 6 distinct experiments
with a total of 18 mice) (Figure 4G). This reduction was of similar
magnitude to that observed with gene silencing of Sema3A (Fig-
ure 4E). Importantly, neutralization of VEGF with a neutralizing
antibody for mouse VEGF164 was not effective at reducing
vascular permeability at this early stage of diabetes (vehicle
versus anti-VEGF: 0.975 ± 0.0707; p = 0.7302; rmNRP1 versus
anti-mVEGF: p = 0.035, n = 5 distinct experiments with a total
of 14 mice). This is likely attributed to the fact that VEGF is not
increased in diabetic retinas at this early time point (8 weeks),
while Sema3A is robustly induced (Figure 2). Together, these
data suggest that neutralization of SEMA3A in the diabetic
retina is an effective strategy to reduce vasogenic edema
(Figure 4H).
Conditional Knockout of Nrp1 Prevents SEMA3A-
Induced Retinal Barrier Function Breakdown
In light of NRP1 being the cognate receptor for SEMA3A, we
sought to determine whether deletion of Nrp1 protects againstd signal depicts leakage of Evans blue/albumin into the retina. Representative
Sema3A effectively reduces endothelial barrier function (3.26–6 hr; 0.048 > p >
0.001; n = 4).
ellular pathway between the cells.
nt of HRMECs with either Sema3A or VEGF leads to robust phosphorylation of
ein VE-cadherin on Tyr731 (I). An additive or enhanced effect was not observed
0.05, **p < 0.01,***p < 0.001 relative to vehicle ± SEM.
scular retraction fibers as determined by VE-cadherin and phalloidin staining
bination of VEGF and Sema3A. Scale bar = 20 mm.
llow lines represent the cell-cell interface.
eath or apoptosis, as determined by assessment of activation of caspase-3.
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Figure 4. Targeted Silencing of Neuron-Derived Sema3A or Intravitreal Neutralization of SEMA3A Efficiently Reduces Diabetes-Induced
Retinal Vascular Permeability
(A) Retinal flatmounts at 8 weeks following STZ-injection show elevated VE-cadherin phosphorylation (linked to higher permeability) on lectin-positive retinal
vessels. Representative images of three independent experiments are shown. Scale bar = 20 mm.
(B) STZ-treated mice show a 56.8% increase in permeability (p = 0.027; n = 4 [12 mice]). Data are represented as mean ± SEM.
(C) Lentiviral vectors with a VSVG capsid exhibit high tropism for RGCs when delivered intravitreally, as depicted by a reporter Lv vector carrying GFP. Scale
bar = 20 mm.
(D and E) A single intravitreal injection of Lv.shSema3A 5 weeks after induction of diabetes lead to a significant 62.3% reduction in retinal Sema3A expression
(p = 0.0014, n = 3) (D) and provoked a proportional 49.5% decrease in vascular leakage (p = 0.022, n = 3 [9 mice]) (E). Data are represented as mean ± SEM.
(legend continued on next page)
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Sema3A Induces Vascular Permeability in DiabetesSEMA3A-induced vascular permeability. Because systemic
germline deletion of Nrp1 is embryonic lethal (Jones et al.,
2008; Kawasaki et al., 1999; Kitsukawa et al., 1997), we gener-
ated a whole-animal tamoxifen-inducible (Tam-inducible) Cre
mouse (TgCre-Esr1) to induce the conditional deletion of exon 2
of Nrp1 (Figure 5A). To validate Cre recombination at the Nrp1
locus and confirm disruption of Nrp1 in vivo, TgCre-Esr1 mice
were crossed with Nrp1fl/fl mice (Gu et al., 2003). Progeny were
given tamoxifen systemically (400 mg/mouse) over a period of 5
consecutive days at 6–9 weeks of age. This dosing regimen
lead to an efficient knockout of Nrp1 in the circulatory system,
as determined by western blot (Figure 5B) and quantitative
PCR (qPCR) (mean fold increase over control ± SEM =
0.07843 ± 0.03176; p = 0.0012) of heart tissue (Figure 5C), and
resulted in a near complete absence of NRP1 in retinal vessels
(Figure 5D). Tam-treated TgCre-Esr1/Nrp1fl/fl mice did not show
any difference in body weight, size, or open-field activity when
compared with littermates from 4–20 weeks of age (data
not shown). Importantly, Tam-treated TgCre-Esr1/Nrp1fl/fl mice
with disrupted retinal vascular Nrp1 were protected against
Sema3A-induced retinal vascular permeability (1.276 ± 0.2901;
p = 0.36; n = 7 distinct experiments with 21 mice) (Figure 5E),
while control Tam-treated TgCre-ESR1/Nrp1+/+ mice showed a
3-fold increase in vascular leakage in response to Sema3A
(2.972 ± 0.2045; p = 0.00065; n = 3 distinct experiments with a
total of 9 mice). Conversely, disruption of Nrp1 did not influ-
ence VEGF-induced vascular retinal permeability (Tam-treated
TgCre-Esr1/Nrp1fl/fl vehicle versus VEGF: 1.814 ± 0.1188, p =
0.0024, n = 3 distinct experiments with a total of 9 mice;
Tam-treated TgCre-Esr1/Nrp1+/+ vehicle versus VEGF: 1.783 ±
0.2440; p = 0.032, n = 3 distinct experiments with a total of
9 mice) (Figure 5F), suggesting that VEGF-induced retinal
vascular permeability does not require NRP1. This is in accor-
dance with previous work (Pan et al., 2007). In line with a role
for NRP1 in mediating Sema3A-induced vascular permeability,
knockdown of Nrp1 in HRMECs by Lv.shNrp1 prevents phos-
phorylation of Src, FAK, and VE-Cadherin (Figures 5G–5I). Effi-
ciency of short hairpin RNA (sh)-mediated knockdown of Nrp1
was validated by qPCR (Figure S4). Collectively, these data
confirm that Sema3A-mediated inner blood-retinal barrier func-
tion breakdown is NRP1 dependent.
DISCUSSION
Therapeutic strategies to treat complications associated with
diabetic retinopathy until recently consisted predominantly in
controlling systemic metabolic deregulation (Silva et al., 2010).
While laser photocoagulation and targeted treatments, such as
locally administered corticosteroids and recently approved
anti-VEGF therapies, are currently available, their off-target
effects underscore the need to explore novel therapeutic ave-
nues. In the present study, we provide evidence that Sema3A
provokes vascular barrier breakdown in the early phases of dia-(F) Vitreal SEMA3A was neutralized with a recombinant mouse (rm) soluble NRP
(G) Intravitreal injection of rmNRP1 in STZmice at weeks 6 and 7 after induction of
(p = 0.012, n = 6 [18mice]). Conversely, injection of a neutralizing antibody against
at this stage of disease when compared to vehicle (p = 0.7302, n = 5 [14 mice]).
(H) Depiction of the magnitude of reversal of pathological vascular permeability w
Cellbetic retinopathy and ultimately precipitates DMEwhen vascular
pericyte coverage is still unperturbed. While the biological func-
tions of semaphorins have been studied for the past 20 years
(Luo et al., 1993), novel physiological roles continue to emerge
(Acevedo et al., 2008; Bernard et al., 2012; Bouvre´e et al.,
2012; Fukushima et al., 2011; Gu et al., 2002; 2003; Guttmann-
Raviv et al., 2007; Joyal et al., 2011; Kim et al., 2011; Le Guelte
et al., 2012; Maione et al., 2009; Matsuoka et al., 2011; Serini
et al., 2003; Suto et al., 2007). We demonstrate that in a healthy
mature retina, Sema3A is modestly expressed, whereas in dia-
betes, retinal ganglion neurons, which are in intimate proximity
of retinal vessels (Sapieha, 2012), significantly increase produc-
tion of this classic guidance cue. Through its cognate receptor
Nrp1, Sema3A provokes loosening of endothelial cell junctions
and leads to vasogenic edema (Figure 5J).
Sema3A presents itself as an attractive candidate for thera-
peutic neutralization in adult ocular vasculopathies, given that
its physiological roles are largely limited to embryogenesis. In
addition, further properties that make Sema3A a noteworthy
drug target are its abilitites to induce apoptosis and promote
cytoskeleton remodeling (Guttmann-Raviv et al., 2007; Klags-
brun and Eichmann, 2005; Miao et al., 1999; Neufeld et al.,
2012), which are both salient features of ischemic and prolifera-
tive retinopathies such as that of diabetes (Duh, 2011; Sapieha
et al., 2010; Wang et al., 2012). Importantly, at the early time
points in disease where levels of SEMA3A are elevated, VEGF
levels remain low and relatively unchanged compared to nondi-
abetic controls. Given these expression kinetics and our data
demonstrating that neutralization of VEGF may be ineffective in
early disease, inhibition of Sema3A may be warranted in the
primary phases of disease when low VEGF levels are not yet
reflective of the level of pathological vascular permeability.
While the introduction of anti-VEGF therapy to attenuate neo-
vascular age-related macular degeneration (AMD), and more
recently DME, has resulted in a profound change in clinical treat-
ment paradigms, inhibition of a molecule that plays key roles in
vascular homeostasis warrants contemplation in a condition
such as diabetes where vascular stability is already compro-
mised. Hence, neutralizing Sema3A instead of currently targeted
factors such vasoprotective and neuroprotective VEGF and
placental growth factor (PlGF) may provide a valid therapeutic
alternative for diabetic retinopathy. Exclusive neutralization of
Sema3A in the early phase of diabetes would thus permit the
baseline levels of VEGF present to play out their protective ocular
and systemic roles (Robinson et al., 2001; Stewart, 2012). Alter-
natively, in later phases of disease, neutralization of Sema3A
may also be sought as an adjunct to currently employed anti-
VEGF therapies such as bevacizumab (Avastin), ranibizumab
(Lucentis), or aflibercept (Eylea), given that both proteins seem
to be present in later stages of disease and have similar effects
on retinal vascular barrier function. In this regard, soluble
NRP1 could be employed as a bivalent semaphorin 3A and
VEGF trap, due to its intrinsic ability to bind both molecules.1 protein employed as a bivalent trap for both SEMA3A and VEGF.
diabetes lead to a 48.1% reduction in retinal permeability at week 8 of diabetes
mouse VEGFwas ineffective at reducing diabetes-induced retinal permeability
Values are expressed relative to vehicle-injected retinas ± SEM.
ith different strategies of SEMA3A neutralization.
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Figure 5. Conditional Knockout of Nrp1 Prevents Sema3A-Induced Retinal Barrier Function Breakdown
Tamoxifen (Tam) was administered systemically during a 5-day period to tamoxifen-inducible Nrp1 floxed B6 mice (TgCre-Esr1/Nrp1fl/fl).
(A) Graphic depiction of the inducible Cre-loxP system where estrogen receptor 1 (Esr1) forms a complex with Cre recombinase; Tam, when available, binds the
Cre-Esr1 complex, allowing its nuclear translocation and the subsequent recombination and/or excision of the floxed target gene Nrp1.
(B) Efficiency of Nrp1 deletion by CRE-Esr1 recombinase is evidenced by decreased Nrp-1 protein.
(C) Similarly, Nrp-1 mRNA transcript is reduced as determined in heart tissue (p = 0.0012; n = 2). Data are represented as mean ± SEM.
(D) Immunofluorescence in retinal cryosections reveals the efficiency of Tam-induced knockdown of Nrp1 in lectin-stained retinal vessels.
(legend continued on next page)
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Sema3A Induces Vascular Permeability in DiabetesUsing Tam-treated TgCre-Esr1/Nrp1fl/fl to conditionally delete
Nrp1 in mature animals, we provide in vivo evidence for the
role of this receptor in mediating the effects of SEMA3A on
vascular barrier function breakdown. NRP1 also acts as a
coreceptor for VEGF165, increasing its affinity toward VEGF
receptor-2 (VEGFR-2), thus enhancing VEGFR-2-mediated
chemotaxis, growth of endothelial cells, and angiogenesis
(Miao et al., 2000; Soker et al., 1998; 2002). However, in our
hands, the effects of VEGF on vascular permeability do not
seem to require NRP1, since Tam-treated TgCre-Esr1/Nrp1fl/fl
mice showed a magnitude of retinal edema identical to that
of control Tam-treated TgCre-Esr1/Nrp1+/+ mice, secondary to
elevated VEGF administration. This is consistent with previous
studies demonstrating that blocking the VEGF or Sema3A bind-
ing sites of NRP1 with distinct monoclonal antibodies had no
effect on VEGF-induced vascular permeability (Pan et al.,
2007). It is important to note that it was previously elegantly
demonstrated that selective deletion of Nrp1 in the endothelium
of adult mice renders them resistant to both Sema3A- and VEGF-
mediated intradermal vascular permeability (Acevedo et al.,
2008). Interestingly, the authors also noted that mice that
received systemic treatment with a monoclonal antibody
directed against Nrp1, known to inhibit VEGF binding, potently
inhibited Sema3A-induced permeability yet had little effect on
VEGF-induced permeability. These discrepancies highlight the
context-dependent contribution of Nrp1 to VEGF-mediated
vascular permeability. It is likely that the point of signaling
convergence lies downstream of Nrp1, given that costimulation
of ECs with both VEGF and SEMA3A does not enhance perme-
ability beyond levels noted when each is applied independently.
Because there is a certain mechanistic overlap in the etiol-
ogies of several ocular vasculopathies, such as neovascular
AMD, diabetic retinopathy, retinal vein occlusions, and retinop-
athy of prematurity, treatment paradigms such as anti-VEGFs
are being used or explored for more than one ocular vasculop-
athy. Similarly, Sema3A neutralization may be useful for treating
vessel leakage and edema associated with neovascular AMD
(Yancopoulos, 2010). Moreover, we have previously demon-
strated in a model of oxygen-induced retinopathy (Smith et al.,
1994) that in late stages of pathological retinal neovasculariza-
tion, neuronal-derived SEMA3A forms a repulsive barrier that
hinders normal revascularization by misdirecting vessels away
from the ischemic retina (Joyal et al., 2011). Hence, inhibition
of Sema3A could potentially simultaneously benefit the two
main pathognomonic features of DR, i.e., barrier function deteri-
oration and pathological preretinal neovascularization, which
separately can lead to loss of vision in diabetes.
By studying neurovascular interplay in diabetes, we obtained
insight into a fundamental neurovascular mechanism that medi-(E) In absence of NRP1, intravitreally administered Sema3A did not increase vas
controls show 3-fold higher vascular leakage (p = 0.00065; n = 3 [9 mice]). Data
(F) Conversely, disruption of Nrp1 did not influence VEGF-induced vascular retina
vascular leakage is independent of NRP1 as previously reported. Data are repre
(G–I) In vitro knockdown of Nrp1 in HRMECs by Lv.shNrp1 prevents phosphoryla
(p = 0.0081; n = 3) (I). Data are represented as mean ± SEM. See Figure S4 for e
(J) Graphic depiction of the main findings of the study. In a healthy mature retin
intimate proximity of retinal vessels significantly increase their production. Throug
vasogenic edema.
Cellates pathological barrier function breakdown in diabetic retinop-
athy. Collectively, our study identifies a therapeutic target,
Sema3A, which may be involved beyond DME in diseases in
which elevated vascular permeability is a contributing factor,
such as neovascular AMD, retinopathy of prematurity, cancer,
and stroke.
EXPERIMENTAL PROCEDURES
For detailed experimental procedures, please see Supplemental Information.
Human Samples
The study conforms to the tenets of the Declaration of Helsinki, and approval
of the human clinical protocol and informed consent was obtained from
the Maisonneuve-Rosemont Hospital (HMR) ethics committee (Ref. CER:
10059).
Vitrectomy
All patients previously diagnosed with DME were followed and operated by a
single vitreoretinal surgeon (F.A.R.). Control patients were undergoing surgical
treatment for nonvascular pathology (ERM or MH) by the same surgeon
(F.A.R.).
Animals
All studies were performed according to the Association for Research in
Vision and Ophthalmology (ARVO) Statement for the Use of Animals in
Ophthalmic and Vision Research. Tamoxifen-inducible (Tam-inducible) Cre
mice (TgCre-Esr1; no. 004682) and neuropilin-1 floxed mice (Nrp1tm2Ddg/J;
no. 005247) were purchased from The Jackson Laboratory.
Streptozotocin Mouse Model
C57BL/6J mice (6–7 weeks old) were weighed, and their baseline glycemia
was measured (Accu-Chek, Roche). Mice were injected intraperitoneally
with streptozotocin (Sigma-Aldrich) for 5 consecutive days at 55 mg/kg.
Laser-Capture Microdissection
Eyes were enucleated from 14-week-old adult C57BL/6J that had been dia-
betic for 8 weeks and flash frozen in optimal cutting temperature compound
(OCT). Sections of 12 mm were dissected with a Zeiss Observer microscope
equipped with a PALM MicroBeam device for laser-capture microdissection.
Assessment of Sema3A Levels by ELISA
Vitreous samples were frozen on dry ice immediately after biopsy and stored
at 80C. ELISA was performed according to manufacturer’s instructions
(Uscn Life Science).
Western Blotting, Immunofluorescence, Real-Time PCR Analysis,
and Antibodies
Please see Supplemental Information.
Evans Blue Permeation Assay
Retinal EB permeation was performed with modifications as described in (Xu
et al., 2001). EB was injected at 45 mg/kg intravenously, and it was allowed to
circulate for 2 hr prior to retinal extraction. Evans blue permeation was quan-
tified by fluorimetry (620 nm max absorbance, 740 nm minimum absorbancecular leakage (p = 0.36; n = 7 [21 mice]), while Tam-treated TgCre-ESR1/Nrp1+/+
are represented as mean ± SEM.
l permeability (p = 0.0024; n = 3 [9 mice]), suggesting that VEGF-induced retinal
sented as mean ± SEM.
tion of Src (p = 0.004; n = 3) (G), FAK (p = 0.0002; n = 3) (H), and VE-cadherin
fficacy of shNrp1-mediated knockdown of Nrp1.
a, levels of Sema3A are low, whereas in diabetes, retinal ganglion neurons in
h NRP1, Sema3A provokes loosening of endothelial cell junctions and leads to
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Sema3A Induces Vascular Permeability in Diabetesbackground) with a TECAN Infinite M1000 PRO. EBP (measured in ul / [g3 hr])
is calculated as (EB [ug] / wet retinal weight [g]) / (plasma EB [ug/ul]3 circula-
tion time [hr]). Evans blue permeation was expressed relative to controls.
Electric Cell-Substrate Impedance Sensing Assay
Real-time analysis of transendothelial electric resistance was performed by
plating HUVECs onto 8W10E+ standard 8-well arrays (Applied BioPhysics)
at a density of 105 cells per well. Please see Supplemental Information.
Preparation of Lentivirus
Viral vectors were produced as previously described by us (Binet et al., 2013;
Joyal et al., 2011). Please see Supplemental Information.
Soluble Recombinant NRP1 and Mouse anti-VEGF
STZ-treated diabetic C57BL/6J mice were intravitreally injected with rmNRP1
from plasmid (Mamluk et al., 2002) or R&D Systems at 6 and 7 weeks after STZ
administration. Specific mouse anti-VEGF was purchased from R&D Systems
(AF-493-NA), and 1 ml was injected at 80 ug/ml. Retinal Evans blue permeation
assay was performed at 8 weeks after STZ treatment as described above.
Statistical Analyses
We used Student’s t test and ANOVA, where appropriate, to compare the
different groups; p < 0.05 was considered statistically different. For ELISA, a
nonparametric Mann-Whitney test was used. Results were expressed as
median and interquartile range (IQR: 25%, 75%).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cmet.2013.09.003.
AUTHOR CONTRIBUTIONS
P.S. and A.C. conceived and designed the experiments. A.C., N.T., C.M., K.M.,
F.A.R., A.D., C.P., E.L., N.S., F. Binet, D.L., V.D.G., and F. Beaudoin performed
the experiments. A.C., N.T., C.M., K.M., C.P., E.L., A.D., F.A.R., and P.S.
analyzed the data. F.A.R. performed all vitreous biopsies. A.C., N.T., C.M.,
and P.S. assembled the figures. P.S. wrote the manuscript.
ACKNOWLEDGMENTS
The University of Montreal, Hospital Maisonneuve-Rosemont and P.S. have
filed a patent pertaining to the results presented in the paper. This work was
supported by operating grants to P.S. from the Canadian Diabetes Association
(OG-3-11-3329-PS), the Canadian Institutes of Health Research (221478), the
Foundation Fighting Blindness Canada, and Les Fonds de Recherche en Oph-
talmologie de l’Universite´ de Montre´al. P.S. holds a Canada Research Chair in
Retinal Cell Biology and The Alcon Research Institute Young Investigator
Award. A.C. is supported by scholarships from the Re´seau de Recherche en
Sante de la Vision du Que´bec (RRSV). N.S. and F.B. hold a Fonds de la Re-
cherche en Sante´ du Que´bec (FRSQ) postdoctoral fellowship. F. Beaudoin is
supported by the The Whitearn Foundation. We thank Wei Li for the illustration
in Figures 2 and 4. We thank Lois E.H. Smith for assessment of Sema3A in
db/db mice. We also give special thanks to Aouatef Benlemmouden for coor-
dinating patients for clinical sampling of vitreous.
Received: April 8, 2013
Revised: July 20, 2013
Accepted: August 23, 2013
Published: October 1, 2013
REFERENCES
Acevedo, L.M., Barillas, S., Weis, S.M., Go¨thert, J.R., and Cheresh, D.A.
(2008). Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts
as a vascular permeability factor. Blood 111, 2674–2680.516 Cell Metabolism 18, 505–518, October 1, 2013 ª2013 Elsevier InAntonetti, D.A., Klein, R., and Gardner, T.W. (2012). Diabetic retinopathy.
N. Engl. J. Med. 366, 1227–1239.
Appleton, B.A., Wu, P., Maloney, J., Yin, J., Liang, W.C., Stawicki, S., Mortara,
K., Bowman, K.K., Elliott, J.M., Desmarais, W., et al. (2007). Structural studies
of neuropilin/antibody complexes provide insights into semaphorin and VEGF
binding. EMBO J. 26, 4902–4912.
Barber, A.J., Lieth, E., Khin, S.A., Antonetti, D.A., Buchanan, A.G., and
Gardner, T.W. (1998). Neural apoptosis in the retina during experimental and
human diabetes. Early onset and effect of insulin. J. Clin. Invest. 102, 783–791.
Barber, A.J., Antonetti, D.A., Kern, T.S., Reiter, C.E., Soans, R.S., Krady, J.K.,
Levison, S.W., Gardner, T.W., and Bronson, S.K. (2005). The Ins2Akita mouse
as a model of early retinal complications in diabetes. Invest. Ophthalmol. Vis.
Sci. 46, 2210–2218.
Bernard, F., Moreau-Fauvarque, C., Heitz-Marchaland, C., Zagar, Y., Dumas,
L., Fouquet, S., Lee, X., Shao, Z., Mi, S., and Che´dotal, A. (2012). Role of trans-
membrane semaphorin Sema6A in oligodendrocyte differentiation and myeli-
nation. Glia 60, 1590–1604.
Binet, F., Mawambo, G., Sitaras, N., Tetreault, N., Lapalme, E., Favret, S.,
Cerani, A., Leboeuf, D., Tremblay, S., Rezende, F., et al. (2013). Neuronal ER
stress impedes myeloid-cell-induced vascular regeneration through IRE1a
degradation of netrin-1. Cell Metab. 17, 353–371.
Bouvre´e, K., Brunet, I., Del Toro, R., Gordon, E., Prahst, C., Cristofaro, B.,
Mathivet, T., Xu, Y., Soueid, J., Fortuna, V., et al. (2012). Semaphorin3A,
Neuropilin-1, and PlexinA1 are required for lymphatic valve formation. Circ.
Res. 111, 437–445.
Cheung, N., and Wong, T.Y. (2008). Diabetic retinopathy and systemic
vascular complications. Prog. Retin. Eye Res. 27, 161–176.
Duh, E.J. (2011). Sema 3A resists retinal revascularization. Blood 117, 5785–
5786.
Eliceiri, B.P., Paul, R., Schwartzberg, P.L., Hood, J.D., Leng, J., and Cheresh,
D.A. (1999). Selective requirement for Src kinases during VEGF-induced
angiogenesis and vascular permeability. Mol. Cell 4, 915–924.
Foxton, R.H., Finkelstein, A., Vijay, S., Dahlmann-Noor, A., Khaw, P.T.,
Morgan, J.E., Shima, D.T., and Ng, Y.S. (2013). VEGF-A is necessary and suf-
ficient for retinal neuroprotection in models of experimental glaucoma. Am. J.
Pathol. 182, 1379–1390.
Fukushima, Y., Okada, M., Kataoka, H., Hirashima, M., Yoshida, Y., Mann, F.,
Gomi, F., Nishida, K., Nishikawa, S., and Uemura, A. (2011). Sema3E-PlexinD1
signaling selectively suppresses disoriented angiogenesis in ischemic retinop-
athy in mice. J. Clin. Invest. 121, 1974–1985.
Gastinger, M.J., Kunselman, A.R., Conboy, E.E., Bronson, S.K., and Barber,
A.J. (2008). Dendrite remodeling and other abnormalities in the retinal ganglion
cells of Ins2 Akita diabetic mice. Invest. Ophthalmol. Vis. Sci. 49, 2635–2642.
Gelfand, M.V., Hong, S., and Gu, C. (2009). Guidance from above: common
cues direct distinct signaling outcomes in vascular and neural patterning.
Trends Cell Biol. 19, 99–110.
Geretti, E., Shimizu, A., and Klagsbrun, M. (2008). Neuropilin structure governs
VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis 11,
31–39.
Gluzman-Poltorak, Z., Cohen, T., Shibuya, M., and Neufeld, G. (2001).
Vascular endothelial growth factor receptor-1 and neuropilin-2 form com-
plexes. J. Biol. Chem. 276, 18688–18694.
Gu, C., Limberg, B.J., Whitaker, G.B., Perman, B., Leahy, D.J., Rosenbaum,
J.S., Ginty, D.D., and Kolodkin, A.L. (2002). Characterization of neuropilin-1
structural features that confer binding to semaphorin 3A and vascular endo-
thelial growth factor 165. J. Biol. Chem. 277, 18069–18076.
Gu, C., Rodriguez, E.R., Reimert, D.V., Shu, T., Fritzsch, B., Richards, L.J.,
Kolodkin, A.L., and Ginty, D.D. (2003). Neuropilin-1 conveys semaphorin and
VEGF signaling during neural and cardiovascular development. Dev. Cell 5,
45–57.
Guttmann-Raviv, N., Shraga-Heled, N., Varshavsky, A., Guimaraes-Sternberg,
C., Kessler, O., and Neufeld, G. (2007). Semaphorin-3A and semaphorin-3F
work together to repel endothelial cells and to inhibit their survival by induction
of apoptosis. J. Biol. Chem. 282, 26294–26305.c.
Cell Metabolism
Sema3A Induces Vascular Permeability in DiabetesHunter, T. (1987). A tail of two src’s: mutatis mutandis. Cell 49, 1–4.
Jones, E.A., Yuan, L., Breant, C., Watts, R.J., and Eichmann, A. (2008).
Separating genetic and hemodynamic defects in neuropilin 1 knockout
embryos. Development 135, 2479–2488.
Joyal, J.-S., Sitaras, N., Binet, F., Rivera, J.C., Stahl, A., Zaniolo, K., Shao, Z.,
Polosa, A., Zhu, T., Hamel, D., et al. (2011). Ischemic neurons prevent vascular
regeneration of neural tissue by secreting semaphorin 3A. Blood 117, 6024–
6035.
Kawasaki, T., Kitsukawa, T., Bekku, Y., Matsuda, Y., Sanbo, M., Yagi, T., and
Fujisawa, H. (1999). A requirement for neuropilin-1 in embryonic vessel forma-
tion. Development 126, 4895–4902.
Kempen, J.H., O’Colmain, B.J., Leske, M.C., Haffner, S.M., Klein, R., Moss,
S.E., Taylor, H.R., and Hamman, R.F.; Eye Diseases Prevalence Research
Group. (2004). The prevalence of diabetic retinopathy among adults in the
United States. Arch. Ophthalmol. 122, 552–563.
Kern, T.S., and Engerman, R.L. (1996). Capillary lesions develop in retina rather
than cerebral cortex in diabetes and experimental galactosemia. Arch.
Ophthalmol. 114, 306–310.
Kim, J., Oh, W.J., Gaiano, N., Yoshida, Y., and Gu, C. (2011). Semaphorin 3E-
Plexin-D1 signaling regulates VEGF function in developmental angiogenesis
via a feedback mechanism. Genes Dev. 25, 1399–1411.
Kitsukawa, T., Shimizu, M., Sanbo, M., Hirata, T., Taniguchi, M., Bekku, Y.,
Yagi, T., and Fujisawa, H. (1997). Neuropilin-semaphorin III/D-mediated che-
morepulsive signals play a crucial role in peripheral nerve projection in mice.
Neuron 19, 995–1005.
Klagsbrun, M., and Eichmann, A. (2005). A role for axon guidance receptors
and ligands in blood vessel development and tumor angiogenesis. Cytokine
Growth Factor Rev. 16, 535–548.
Klagsbrun, M., Takashima, S., and Mamluk, R. (2002). The role of neuropilin in
vascular and tumor biology. Adv. Exp. Med. Biol. 515, 33–48.
Klebanov, O., Nitzan, A., Raz, D., Barzilai, A., and Solomon, A.S. (2009).
Upregulation of Semaphorin 3A and the associated biochemical and cellular
events in a rat model of retinal detachment. Graefes Arch. Clin. Exp.
Ophthalmol. 247, 73–86.
Koppel, A.M., and Raper, J.A. (1998). Collapsin-1 covalently dimerizes, and
dimerization is necessary for collapsing activity. J. Biol. Chem. 273, 15708–
15713.
Le Guelte, A., Galan-Moya, E.M., Dwyer, J., Treps, L., Kettler, G., Hebda, J.K.,
Dubois, S., Auffray, C., Chneiweiss, H., Bidere, N., and Gavard, J. (2012).
Semaphorin 3A elevates endothelial cell permeability through PP2A inactiva-
tion. J. Cell Sci. 125, 4137–4146.
Lee, P., Goishi, K., Davidson, A.J., Mannix, R., Zon, L., and Klagsbrun, M.
(2002). Neuropilin-1 is required for vascular development and is a mediator
of VEGF-dependent angiogenesis in zebrafish. Proc. Natl. Acad. Sci. USA
99, 10470–10475.
Luo, Y., Raible, D., and Raper, J.A. (1993). Collapsin: a protein in brain that in-
duces the collapse and paralysis of neuronal growth cones. Cell 75, 217–227.
Maione, F., Molla, F., Meda, C., Latini, R., Zentilin, L., Giacca, M., Seano, G.,
Serini, G., Bussolino, F., and Giraudo, E. (2009). Semaphorin 3A is an endog-
enous angiogenesis inhibitor that blocks tumor growth and normalizes tumor
vasculature in transgenic mouse models. J. Clin. Invest. 119, 3356–3372.
Mamluk, R., Gechtman, Z., Kutcher, M.E., Gasiunas, N., Gallagher, J., and
Klagsbrun, M. (2002). Neuropilin-1 binds vascular endothelial growth factor
165, placenta growth factor-2, and heparin via its b1b2 domain. J. Biol.
Chem. 277, 24818–24825.
Martin, D.F., Maguire, M.G., Ying, G.S., Grunwald, J.E., Fine, S.L., Jaffe, G.J.,
and Jaffe, G.J.; CATTResearchGroup. (2011). Ranibizumab and bevacizumab
for neovascular age-related macular degeneration. N. Engl. J. Med. 364,
1897–1908.
Martin, D.F., Maguire, M.G., Fine, S.L., Ying, G.S., Jaffe, G.J., Grunwald, J.E.,
Toth, C., Redford, M., and Ferris, F.L., 3rd.; Comparison of Age-related
Macular Degeneration Treatments Trials (CATT) Research Group. (2012).
Ranibizumab and bevacizumab for treatment of neovascular age-relatedmac-
ular degeneration: two-year results. Ophthalmology 119, 1388–1398.CellMatsuoka, R.L., Nguyen-Ba-Charvet, K.T., Parray, A., Badea, T.C., Che´dotal,
A., and Kolodkin, A.L. (2011). Transmembrane semaphorin signalling controls
laminar stratification in the mammalian retina. Nature 470, 259–263.
Miao, H.Q., Soker, S., Feiner, L., Alonso, J.L., Raper, J.A., and Klagsbrun, M.
(1999). Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothe-
lial cell motility: functional competition of collapsin-1 and vascular endothelial
growth factor-165. J. Cell Biol. 146, 233–242.
Miao, H.Q., Lee, P., Lin, H., Soker, S., and Klagsbrun, M. (2000). Neuropilin-1
expression by tumor cells promotes tumor angiogenesis and progression.
FASEB J. 14, 2532–2539.
Mima, A., Qi, W., Hiraoka-Yamomoto, J., Park, K., Matsumoto, M., Kitada, M.,
Li, Q., Mizutani, K., Yu, E., Shimada, T., et al. (2012). Retinal not systemic
oxidative and inflammatory stress correlated with VEGF expression in rodent
models of insulin resistance and diabetes. Invest. Ophthalmol. Vis. Sci. 53,
8424–8432.
Moss, S.E., Klein, R., and Klein, B.E. (1998). The 14-year incidence of visual
loss in a diabetic population. Ophthalmology 105, 998–1003.
Murakami, M., Nguyen, L.T., Zhuang, Z.W., Moodie, K.L., Carmeliet, P., Stan,
R.V., and Simons, M. (2008). The FGF system has a key role in regulating
vascular integrity. J. Clin. Invest. 118, 3355–3366.
Neufeld, G., Sabag, A.D., Rabinovicz, N., and Kessler, O. (2012). Semaphorins
in angiogenesis and tumor progression. Cold Spring Harb Perspect Med 2,
a006718.
Pan, Q., Chanthery, Y., Liang, W.C., Stawicki, S., Mak, J., Rathore, N., Tong,
R.K., Kowalski, J., Yee, S.F., Pacheco, G., et al. (2007). Blocking neuropilin-1
function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer
Cell 11, 53–67.
Potter, M.D., Barbero, S., and Cheresh, D.A. (2005). Tyrosine phosphorylation
of VE-cadherin prevents binding of p120- and beta-catenin and maintains the
cellular mesenchymal state. J. Biol. Chem. 280, 31906–31912.
Robinson, G.S., Ju, M., Shih, S.C., Xu, X., McMahon, G., Caldwell, R.B., and
Smith, L.E. (2001). Nonvascular role for VEGF: VEGFR-1, 2 activity is critical
for neural retinal development. FASEB J. 15, 1215–1217.
Saint-Geniez, M., Maharaj, A.S., Walshe, T.E., Tucker, B.A., Sekiyama, E.,
Kurihara, T., Darland, D.C., Young, M.J., and D’Amore, P.A. (2008).
Endogenous VEGF is required for visual function: evidence for a survival role
on mu¨ller cells and photoreceptors. PLoS ONE 3, e3554.
Sapieha, P. (2012). Eyeing central neurons in vascular growth and reparative
angiogenesis. Blood 120, 2182–2194.
Sapieha, P., Sirinyan, M., Hamel, D., Zaniolo, K., Joyal, J.-S., Cho, J.-H.,
Honore´, J.-C., Kermorvant-Duchemin, E., Varma, D.R., Tremblay, S., et al.
(2008). The succinate receptor GPR91 in neurons has a major role in retinal
angiogenesis. Nat. Med. 14, 1067–1076.
Sapieha, P., Hamel, D., Shao, Z., Rivera, J.C., Zaniolo, K., Joyal, J.S., and
Chemtob, S. (2010). Proliferative retinopathies: angiogenesis that blinds. Int.
J. Biochem. Cell Biol. 42, 5–12.
Sapieha, P., Chen, J., Stahl, A., Seaward, M.R., Favazza, T.L., Juan, A.M.,
Hatton, C.J., Joyal, J.S., Krah, N.M., Dennison, R.J., et al. (2012). Omega-3
polyunsaturated fatty acids preserve retinal function in type 2 diabetic mice.
Nutr Diabetes 2, e36.
Scheppke, L., Aguilar, E., Gariano, R.F., Jacobson, R., Hood, J., Doukas, J.,
Cao, J., Noronha, G., Yee, S., Weis, S., et al. (2008). Retinal vascular perme-
ability suppression by topical application of a novel VEGFR2/Src kinase inhib-
itor in mice and rabbits. J. Clin. Invest. 118, 2337–2346.
Schlaepfer, D.D., Hanks, S.K., Hunter, T., and van der Geer, P. (1994). Integrin-
mediated signal transduction linked to Ras pathway by GRB2 binding to focal
adhesion kinase. Nature 372, 786–791.
Serini, G., Valdembri, D., Zanivan, S., Morterra, G., Burkhardt, C., Caccavari,
F., Zammataro, L., Primo, L., Tamagnone, L., Logan, M., et al. (2003). Class
3 semaphorins control vascular morphogenesis by inhibiting integrin function.
Nature 424, 391–397.
Silva, P.S., Cavallerano, J.D., Sun, J.K., Aiello, L.M., and Aiello, L.P. (2010).
Effect of systemic medications on onset and progression of diabetic retinop-
athy. Nat. Rev. Endocrinol. 6, 494–508.Metabolism 18, 505–518, October 1, 2013 ª2013 Elsevier Inc. 517
Cell Metabolism
Sema3A Induces Vascular Permeability in DiabetesSmith, L.E., Wesolowski, E., McLellan, A., Kostyk, S.K., D’Amato, R., Sullivan,
R., and D’Amore, P.A. (1994). Oxygen-induced retinopathy in the mouse.
Invest. Ophthalmol. Vis. Sci. 35, 101–111.
Soker, S., Takashima, S., Miao, H.Q., Neufeld, G., and Klagsbrun, M. (1998).
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-
specific receptor for vascular endothelial growth factor. Cell 92, 735–745.
Soker, S., Miao, H.Q., Nomi, M., Takashima, S., and Klagsbrun, M. (2002).
VEGF165 mediates formation of complexes containing VEGFR-2 and
neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem. 85,
357–368.
Stahl, A., Connor, K.M., Sapieha, P., Chen, J., Dennison, R.J., Krah, N.M.,
Seaward, M.R., Willett, K.L., Aderman, C.M., Guerin, K.I., et al. (2010). The
mouse retina as an angiogenesis model. Invest. Ophthalmol. Vis. Sci. 51,
2813–2826.
Stewart, M.W. (2012). The expanding role of vascular endothelial growth factor
inhibitors in ophthalmology. Mayo Clin. Proc. 87, 77–88.518 Cell Metabolism 18, 505–518, October 1, 2013 ª2013 Elsevier InSuto, F., Tsuboi, M., Kamiya, H., Mizuno, H., Kiyama, Y., Komai, S., Shimizu,
M., Sanbo, M., Yagi, T., Hiromi, Y., et al. (2007). Interactions between plexin-
A2, plexin-A4, and semaphorin 6A control lamina-restricted projection of
hippocampal mossy fibers. Neuron 53, 535–547.
Takahashi, T., Fournier, A., Nakamura, F., Wang, L.H., Murakami, Y., Kalb,
R.G., Fujisawa, H., and Strittmatter, S.M. (1999). Plexin-neuropilin-1 com-
plexes form functional semaphorin-3A receptors. Cell 99, 59–69.
Vieira, J.M., Schwarz, Q., and Ruhrberg, C. (2007). Role of the neuropilin
ligands VEGF164 and SEMA3A in neuronal and vascular patterning in the
mouse. Novartis Found. Symp. 283, 230–235, discussion 235–241.
Wang, S., Park, J.K., and Duh, E.J. (2012). Novel targets against retinal angio-
genesis in diabetic retinopathy. Curr. Diab. Rep. 12, 355–363.
Xu, Q., Qaum, T., and Adamis, A.P. (2001). Sensitive blood-retinal barrier
breakdown quantitation using Evans blue. Invest. Ophthalmol. Vis. Sci. 42,
789–794.
Yancopoulos, G.D. (2010). Clinical application of therapies targeting VEGF.
Cell 143, 13–16.c.
